Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Incyte Corporation INCY

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.


Recent & Breaking News (NDAQ:INCY)

Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs

Business Wire 1 day ago

Incyte to Present at Upcoming Investor Conference

Business Wire January 24, 2023

Incyte to Report Fourth Quarter and Year-End 2022 Financial Results

Business Wire January 17, 2023

Incyte to Present at Upcoming Investor Conferences

Business Wire December 15, 2022

Incyte's Novel Mutant CALR Antibody Unveiled at ASH 2022 Plenary Scientific Session

Business Wire December 11, 2022

Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis (MF) Presented at ASH 2022

Business Wire December 10, 2022

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

PR Newswire December 5, 2022

Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia

Business Wire December 2, 2022

Incyte to Present at Upcoming Investor Conferences

Business Wire November 17, 2022

Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors

Business Wire November 7, 2022

Data From Incyte's Oncology Portfolio to Be Presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Business Wire November 7, 2022

More than 50 Abstracts from Incyte's Robust Oncology Portfolio to be Featured at the 64th ASH Annual Meeting

Business Wire November 3, 2022

Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

Business Wire November 1, 2022

Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura(TM)) in Vitiligo Published in New England Journal of Medicine

Business Wire October 19, 2022

Incyte to Report Third Quarter Financial Results

Business Wire October 11, 2022

Knight Therapeutics Announces Regulatory Submission for Tafasitamab in Brazil

GlobeNewswire October 6, 2022

Incyte Names New Member to Its Board of Directors

Business Wire October 4, 2022

Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody

Business Wire October 3, 2022

Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement

Business Wire August 26, 2022

Data from Incyte's Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress

Business Wire August 24, 2022